Asthma‐related non‐fatal serious adverse events · children with chronic asthma
1 finding from 1 review
Adverse events—'serious'—320/94 Duration of 10 months3 · COPD
Budesonide/formoterol (BDF) showed no clear difference in adverse events—'serious'—320/94 Duration of 10 months3 compared with placebo (low certainty).
1 finding from 1 review
OR 1.17 [0.95, 1.45]
2476 participants
Low
Adverse events—'serious'—160/94 Duration of nine months 3 · COPD
Budesonide/formoterol (BDF) showed no clear difference in adverse events—'serious'—160/94 Duration of nine months 3 compared with placebo (low certainty).
1 finding from 1 review
OR 1.2 [0.89, 1.63]
1556 participants
Low
Adverse event—any—320/94 Duration of nine months 3 · COPD
Budesonide/formoterol (BDF) may leads to higher adverse event—any—320/94 Duration of nine months 3 compared with placebo (low certainty).
1 finding from 1 review
OR 1.42 [1.16, 1.74]
1552 participants
Low
Adverse event—any—160/94 Duration of nine months 3 · COPD
Budesonide/formoterol (BDF) may leads to higher adverse event—any—160/94 Duration of nine months 3 compared with placebo (low certainty).
1 finding from 1 review
OR 1.32 [1.08, 1.61]
1556 participants
Low
Adverse events at study endpoint · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse event—any—400/103 Duration of six months compared with placebo (low certainty).
2 findings from 1 review
OR 0.98 [0.75, 1.3]
890 participants
Low
OR 0.82 [0.62, 1.09]
894 participants
Low
Adverse events—serious—400/103 Duration of six months · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—400/103 Duration of six months compared with placebo (low certainty).
1 finding from 1 review
OR 1.09 [0.66, 1.79]
890 participants
Low
Adverse events—serious—200/103 Duration of six months · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—200/103 Duration of six months compared with placebo (low certainty).
1 finding from 1 review
OR 0.71 [0.41, 1.23]
894 participants
Low
Intervention not reported
SAEs ‐ formoterol versus placebo ( · patients with chronic asthma
The intervention leads to higher SAEs ‐ formoterol versus placebo ( (high certainty).
1 finding from 1 review
Intervention not reported
SAEs ‐ formoterol versus salbutamol ( · patients with chronic asthma
The intervention showed no clear difference in SAEs ‐ formoterol versus salbutamol ( (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality (all‐cause) ‐ formoterol versus placebo ( · patients with chronic asthma
The intervention showed no clear difference in mortality (all‐cause) ‐ formoterol versus placebo ( (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality (all‐cause) ‐ formoterol versus salbutamol ( · patients with chronic asthma
The intervention showed no clear difference in mortality (all‐cause) ‐ formoterol versus salbutamol ( (moderate certainty).
1 finding from 1 review
Intervention not reported
SAEs ‐ formoterol versus placebo ( · patients with chronic asthma (children)
The intervention leads to higher SAEs ‐ formoterol versus placebo ( (high certainty).
1 finding from 1 review
Intervention not reported
SAEs ‐ formoterol versus salbutamol · patients with chronic asthma (children)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in exacerbations requiring steroids or antibiotics or both: number of… compared with aclidinium alone (moderate certainty).
1 finding from 1 review
Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in exacerbations requiring steroids or antibiotics or both: number of… compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol leads to higher quality of life: number of participants with clinically significant… compared with placebo (high certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in hospital admissions due to exacerbations: number of participants compared with placebo (moderate certainty).
1 finding from 1 review
Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol leads to higher improvement in symptoms: number of participants with clinically… compared with placebo (high certainty).
1 finding from 1 review